Newron Pharmaceuticals SpA (CHIX:NWRNZ) Construction In Progress: CHF0.00 Mil (As of Dec. 2025)


CHIX:NWRNZ Newron Pharmaceuticals SpA CHIX:NWRNZ
48 GF Score
Price CHF12.62
GF Value CHF12.89
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Construction In Progress?

Newron Pharmaceuticals SpA CHIX:NWRNZ -1.10% 48 Construction In Progress is CHF0.00 Mil as of Dec. 2025. GuruFocus rates CHIX:NWRNZ with a GF Score™ of 48/100 and a GF Value™ of CHF12.89 (Fairly Valued). The stock has 5 warning signs investors should review.

Newron Pharmaceuticals SpA Construction In Progress Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Construction In Progress Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:NWRNZ
48GF Score
Newron Pharmaceuticals SpA CHIX:NWRNZ
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of CHF0.00 Mil mean?
Newron Pharmaceuticals SpA (CHIX:NWRNZ) has a Construction In Progress of CHF0.00 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's Construction In Progress too high?
Newron Pharmaceuticals SpA's current Construction In Progress is CHF0.00 Mil. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Construction In Progress compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Construction In Progress of CHF0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current Construction In Progress is CHF0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (CHIX:NWRNZ) is currently considered Fairly Valued. The stock's GF Value™ is CHF12.89, compared to a current price of CHF12.62 — trading 2.1% below its estimated fair value. The current Construction In Progress is CHF0.00 Mil. Newron Pharmaceuticals SpA's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (CHIX:NWRNZ), the current Construction In Progress is CHF0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (CHIX:NWRNZ) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of CHF12.62 is trading 2.1% below its estimated GF Value™ of CHF12.89. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for CHIX:NWRNZ:

  • Construction In Progress: CHF0.00 Mil
  • GF Value™: CHF12.89 vs. price of CHF12.62 (2.1% below fair value)
  • GF Score™: 48/100 with 5 warning signs

No single metric tells the full story. See the CHIX:NWRNZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
48GF Score

Get the complete analysis for CHIX:NWRNZ

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF12.62
Price
CHF12.89
GF Value